DMEK
What Is Descemet Membrane Endothelial Keratoplasty
Descemet membrane endothelial keratoplasty (DMEK) is the most advanced form of partial-thickness corneal transplant available today, designed to replace only the thin inner layer of the cornea responsible for keeping it clear. The cornea has five layers, and the innermost layer, the endothelium, is a single sheet of cells responsible for pumping fluid out of the cornea to maintain its clarity. When these endothelial cells become damaged or die, they cannot regenerate on their own. Fluid builds up within the cornea, causing it to swell and cloud.
Unlike a full-thickness corneal transplant, which replaces all five layers of the cornea, DMEK transplants only the Descemet membrane and endothelial cell layer. This donor tissue is extremely thin, measuring roughly 10 to 15 microns. Because DMEK avoids cutting through the full cornea, it preserves the eye's structural integrity, results in fewer sutures, and typically leads to better visual outcomes with a lower risk of graft rejection. According to the EBAA 2024 Statistical Report, DMEK has become the most commonly performed corneal transplant procedure in the United States for treating endothelial disease.
DMEK represents the latest refinement in a family of endothelial transplant procedures. Earlier techniques such as DSEK also replaced the inner corneal layers but included an additional layer of stromal tissue, making the graft thicker. DMEK eliminates that extra tissue, resulting in a thinner graft that more closely matches the cornea's natural anatomy.
Conditions DMEK Treats
Fuchs dystrophy is the most common reason patients undergo DMEK. In this inherited condition, endothelial cells gradually deteriorate over years, causing the cornea to swell, particularly in the morning. Patients often notice hazy vision, glare sensitivity, and difficulty with fine visual tasks. DMEK replaces the dysfunctional endothelial layer with healthy donor tissue, directly addressing the root cause of vision loss.
Bullous keratopathy occurs when the endothelium fails after previous eye surgery, most commonly cataract surgery. The cornea becomes waterlogged and develops painful blisters on its surface. DMEK can restore endothelial function and relieve both the visual impairment and the chronic discomfort associated with this condition.
Patients whose previous endothelial transplant or full-thickness graft has failed may be candidates for a repeat procedure using DMEK. Because the technique involves minimal tissue manipulation, it can sometimes be performed even in eyes with a complex surgical history, though candidacy depends on the individual case.
Who Is a Candidate for DMEK
The best candidates for DMEK are patients whose vision loss is primarily caused by endothelial cell dysfunction, with an otherwise healthy cornea and intact anterior segment. Patients with Fuchs dystrophy who have progressed to the point where glasses or eye drops no longer provide adequate vision are among the most common candidates.
Certain eye conditions can make DMEK more technically challenging or less predictable, including prior glaucoma surgery with tube shunts or filtering blebs, significant iris defects or previous complex anterior segment surgery, eyes with anterior chamber intraocular lenses, and extensive corneal scarring that extends beyond the endothelial layer. In some of these situations, a different endothelial transplant technique or a full-thickness corneal transplant may be more appropriate.
Before recommending DMEK, we perform a detailed evaluation that includes specular microscopy to measure your endothelial cell count, pachymetry to assess corneal thickness, and optical coherence tomography to examine corneal layers in cross-section. These measurements help confirm whether endothelial dysfunction is the primary cause of your symptoms.
How DMEK Is Performed
The donor tissue is carefully harvested from a human cornea provided through an eye bank. The surgeon or a trained technician peels the Descemet membrane and its attached endothelial cells away from the donor cornea, creating an ultra-thin tissue graft. This delicate preparation is one of the most technically demanding steps of the procedure.
During surgery, the diseased Descemet membrane and endothelium are gently stripped from the inner surface of your cornea through a small incision. The donor tissue graft, which naturally scrolls into a tight roll, is loaded into an injector and inserted into the anterior chamber of the eye. Once inside, the surgeon carefully unfurls and positions the graft against the back surface of your cornea. An air bubble is then injected beneath the graft to press it into place.
Following surgery, you will need to lie face-up for several hours and continue this positioning at home as directed, usually for the first 24 to 48 hours. The air bubble acts as a natural bandage, holding the donor tissue against your cornea while it attaches. You will use prescribed anti-inflammatory and antibiotic eye drops during the recovery period.
Frequently Asked Questions
Both DMEK and DSAEK replace the dysfunctional inner corneal layer, but DMEK transplants a thinner graft that produces sharper visual results on average and carries a lower rejection rate. However, DSAEK may be preferred in certain complex eyes where graft manipulation is more difficult. You can learn more about the differences between DMEK and DSAEK.
The most common complication is partial graft detachment, which occurs in approximately 15 to 30 percent of cases and typically requires a rebubbling procedure. Primary graft failure, where the donor cells do not survive, is uncommon but may require a repeat transplant. Graft rejection is possible with any transplant but occurs less frequently with DMEK than with other corneal transplant techniques.
Most patients do require glasses for their best vision after DMEK, particularly for reading. Because the procedure addresses the inner corneal layer and does not reshape the front surface, your pre-existing refractive error will generally remain unchanged. The good news is that DMEK adds very little new astigmatism.
Studies show that DMEK grafts have a five-year survival rate above 90 percent, with many grafts continuing to function well beyond a decade. Graft longevity depends on factors such as the quality of the donor tissue, the health of your eye, and adherence to your post-operative drop regimen.
DMEK is performed under local anesthesia, so you should not feel pain during the procedure itself. Most patients experience only mild pressure or awareness of light. After surgery, you may have some scratchy discomfort and sensitivity to light for a few days, which is well managed with lubricating drops and the prescribed medications.
What our Patients say
4.8
Reviews
(3645)